ENTA (Enanta Pharmaceuticals) Other Long-Term Liabilities: $89.89 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ENTA Enanta Pharmaceuticals Inc ENTA
56 GF Score
Price $13.20
GF Value $7.89
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Enanta Pharmaceuticals Other Long-Term Liabilities?

Enanta Pharmaceuticals ENTA -2.98% 56 Other Long-Term Liabilities is $89.89 Mil as of Jun. 2026. GuruFocus rates ENTA with a GF Score™ of 56/100 and a GF Value™ of $7.89 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Enanta Pharmaceuticals's other long-term liabilities for the quarter that ended in Jun. 2026 was $89.89 Mil.

Enanta Pharmaceuticals's quarterly other long-term liabilities declined from Dec. 2025 ($104.40 Mil) to Mar. 2026 ($98.90 Mil) and declined from Mar. 2026 ($98.90 Mil) to Jun. 2026 ($89.89 Mil).

Enanta Pharmaceuticals's annual other long-term liabilities declined from Sep. 2023 ($161.52 Mil) to Sep. 2024 ($136.36 Mil) and declined from Sep. 2024 ($136.36 Mil) to Sep. 2025 ($112.70 Mil).

Enanta Pharmaceuticals Other Long-Term Liabilities Related Terms

Enanta Pharmaceuticals Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Enanta Pharmaceuticals's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enanta Pharmaceuticals Other Long-Term Liabilities Chart

Enanta Pharmaceuticals Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.06 1.88 161.52 136.36 112.70

Enanta Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 121.55 112.70 104.40 98.90 89.89
ENTA
56GF Score
Enanta Pharmaceuticals Inc ENTA
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Enanta Pharmaceuticals Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of $89.89 Mil mean?
Enanta Pharmaceuticals (ENTA) has a Other Long-Term Liabilities of $89.89 Mil as of Jun. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Enanta Pharmaceuticals and its competitors.
Is Enanta Pharmaceuticals' Other Long-Term Liabilities too high?
Enanta Pharmaceuticals' current Other Long-Term Liabilities is $89.89 Mil. Overall, Enanta Pharmaceuticals has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Enanta Pharmaceuticals' Other Long-Term Liabilities compare to LXEO and XFOR?
Enanta Pharmaceuticals' Other Long-Term Liabilities of $89.89 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Biotechnology company?
A good Other Long-Term Liabilities depends on the Biotechnology industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Enanta Pharmaceuticals and its competitors. Enanta Pharmaceuticals's current Other Long-Term Liabilities is $89.89 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enanta Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Enanta Pharmaceuticals (ENTA) is currently considered Significantly Overvalued. The stock's GF Value™ is $7.89, compared to a current price of $13.20 — trading 67.2% above its estimated fair value. The current Other Long-Term Liabilities is $89.89 Mil. Enanta Pharmaceuticals' overall GF Score™ is 56/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Enanta Pharmaceuticals (ENTA), the current Other Long-Term Liabilities is $89.89 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Enanta Pharmaceuticals (ENTA) Overvalued in 2026?

Based on GuruFocus' analysis, Enanta Pharmaceuticals stock appears to be overvalued. The current stock price of $13.20 is trading 67.2% above its estimated GF Value™ of $7.89. GuruFocus considers Enanta Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for ENTA:

  • Other Long-Term Liabilities: $89.89 Mil
  • GF Value™: $7.89 vs. price of $13.20 (67.2% above fair value)
  • GF Score™: 56/100 with 6 warning signs

No single metric tells the full story. See the ENTA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Enanta Pharmaceuticals Business Description

Other Exchanges 9EP:Germany
Address 4 Kingsbury Avenue, Watertown, MA, USA, 02472
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
56GF Score

Get the complete analysis for ENTA

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.20
Price
$7.89
GF Value